IXICO PLC Advancing health by turning data into clinically meaningful information
IXICO plc
Annual Report & Accounts 2021
IXICO is a trusted partner to the global pharmaceutical industry, supporting their development of new treatments for neurological diseases with unmet clinical needs.
We develop and deploy therapeutic
specific AI algorithms to improve insights
for better outcomes in neurological
clinical trials.
Strategic report | 01-30 | Governance | 31-48 | Financial statements | 49-92 | |||||||||||||||||||
02 | What we do | 32 | Chairman's statement | 50 | Independent Auditor's Report | |||||||||||||||||||
03 | How we do it | 34 | Board of Directors | to the Members of IXICO plc | ||||||||||||||||||||
04 | Business model | 36 | Directors' Report | 58 | Consolidated Statement of | |||||||||||||||||||
06 | Chief Executive's statement | 39 | Stakeholder engagement | Comprehensive Income | ||||||||||||||||||||
08 | Our five-point strategic growth plan | 42 | Directors' Remuneration Report | 59 | Consolidated Statement of Financial Position | |||||||||||||||||||
10 | Market review and opportunities | 44 | Corporate Governance Report | 60 | Company Statement of Financial Position | |||||||||||||||||||
12 | Technology and innovation | 48 | Statement of Directors' Responsibilities | 61 | Consolidated Statement of Changes in Equity | |||||||||||||||||||
18 | Environmental, Social and Governance | 62 | Company Statement of Changes in Equity | |||||||||||||||||||||
22 | People and culture | 63 | Consolidated and Company Statements of | |||||||||||||||||||||
24 | Financial review | Cash Flows | ||||||||||||||||||||||
27 | Risk management | 64 | Notes to the financial statements | |||||||||||||||||||||
27 | Principal risks and uncertainties | 92 | Addresses and advisers |
Strategic report
- What we do
- How we do it
- Business model
- Chief Executive's statement
- Our five-point strategic growth plan
- Market review and opportunities
- Technology and innovation
- Environmental, Social and Governance
- People and culture
- Financial review
- Risk management
- Principal risks and uncertainties
Governancereport Strategic
statements Financial
IXICO plcAnnual Report & Accounts 2021 | 01 |
Strategic report
What we do
Advanced analytics.
Supporting our clients in their clinical decisions
Our specialist data analytics services and AI technologies are supporting some of the most important neurological clinical trials.
Intelligent insights.
Bringing safe and effective treatment to patients sooner
We are dedicated to enhancing insights in neuroscience.
We measure specific imaging biomarkers to enhance understanding of disease progression and the efficacy and safety of drug candidates.
Find out more in our technology and innovation section on pages 12 to 17
02 | IXICO plcAnnual Report & Accounts 2021 |
How we do it
We help global biopharma clients to
get more from their clinical development
programmes through...
Our services
We provide essential services to biopharmaceutical companies engaged in drug development in neuroscience, providing analysis of medical image data generated in a clinical study. Our extensive experience in defining and delivering biomarker measurements in early-phase clinical development and our bespoke TrialTracker data management platform means we are perfectly placed to deliver robust and regulatory compliant data in all phases of clinical trials.
The outputs from our data analyses are used to improve patient selection, monitor safety and assess clinical
efficacy of the drug being trialled, and to support post-marketing surveillance activities.
Governancereport Strategic
statements Financial
CLINICAL PROGRAMME | SITE SETUP AND | PROJECT | ||||||||||||||||||
DESIGN AND CONSULTATION | MANAGEMENT | MANAGEMENT | ||||||||||||||||||
Drawing on our proven neuroscience | We design and deploy harmonised | Our team ensures the efficient | ||||||||||||||||||
expertise and experience, we enable our | image acquisition protocols across | set-up and ongoing delivery of | ||||||||||||||||||
clients to optimise biomarker | multiple international sites. | our services to clinical studies. | ||||||||||||||||||
measurement. |
READING & | |||||||||||||||||||
REGULATORY | DATA MANAGEMENT | ||||||||||||||||||
PATHWAY | AND QUALITY CONTROL | ANALYSIS | |||||||||||||||||
Our service supports deployment | Image and data quality are | We develop and deploy AI data analysis | |||||||||||||||||
of imaging biomarkers within | assessed through our proprietary | tools and neuroradiology reading | |||||||||||||||||
a regulatory-compliant framework. | digital platform, TrialTracker. | workflows tailored to the study | |||||||||||||||||
requirements. |
IXICO plcAnnual Report & Accounts 2021 | 03 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
IXICO plc published this content on 07 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 December 2021 13:38:02 UTC.
